Program
sapanisertib
Also written as “Sapanisertib”, “MLN0128” and “TAK-128”.
Its studies are mostly in Breast Neoplasms · Endometrial Neoplasms · Diabetic Neuropathies · Carcinoma, Non-Small-Cell Lung · Clear-cell metastatic renal cell carcinoma, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Takeda | 80 open or running | phase 2since Sep 27, 2005 | Sep 27, 2005 | none ahead |
| Calithera Biosciences | 30 open or running | phase 2since Apr 28, 2016 | Jul 21, 2014 | none ahead |
| Faeth Therapeutics | 32 open or running | phase 2since Feb 7, 2022 | Feb 7, 2022 | Sep 2028phase 2 · NCT06463028 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 27, 2005First study: phase 2 study in Diabetic NeuropathiesNew to TakedaTakeda · NCT00229437 · 343 enrolled · United States, Canada
- Sep 17, 2008Phase 2 study in Diabetic NeuropathiesTakeda · NCT00756041 · 221 enrolled
- Jan 27, 2010Phase 1 study in Advanced Solid MalignanciesTakeda · NCT01058707 · 198 enrolled · United States, Spain
- May 5, 2010Phase 1 study in Multiple MyelomaTakeda · NCT01118689 · 39 enrolled · United States
- Feb 21, 2011Phase 1 study in Hematologic NeoplasmsTakeda · NCT01351350 · 68 enrolled · United States
- Jul 10, 2013Phase 1 study in Advanced Nonhematologic MalignanciesTakeda · NCT01899053 · 101 enrolled · United States, Spain, United Kingdom
- Jul 21, 2014Calithera Biosciences's first study: phase 1 study in Advanced Solid TumorsNew to Calithera BiosciencesCalithera Biosciences · NCT02197572 · 44 enrolled · United States
- Mar 25, 20162 phase 2 studiesTakeda · NCT02724020, NCT02725268
- Apr 28, 2016Phase 2 study in Breast NeoplasmsCalithera Biosciences · NCT02756364 · 141 enrolled · United States, Spain
- Dec 7, 2017Phase 1 study in Advanced Nonhematological NeoplasmsCalithera Biosciences · NCT03370302 · 28 enrolled · Japan, Korea, Republic of, Taiwan
- Feb 7, 2022Faeth Therapeutics's first study: phase 2 study in Carcinoma, Non-Small-Cell LungNew to Faeth TherapeuticsFaeth Therapeutics · NCT05275673 · 7 enrolled · United States
- Jun 11, 2024Phase 2 study in Endometrial NeoplasmsFaeth Therapeutics · NCT06463028 · 40 planned · United States
- Apr 17, 2026Phase 2 study in Breast NeoplasmsFaeth Therapeutics · NCT07558733 · 32 planned · United States
Ahead
- Sep 2028Primary completion: phase 2 study in Endometrial NeoplasmsFaeth Therapeutics · NCT06463028
- May 2029Primary completion: phase 2 study in Breast NeoplasmsFaeth Therapeutics · NCT07558733
TargetBeta
“Serine/threonine-protein kinase mTOR inhibitor”ChEMBL 37, by rule
Other programs on MTOR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Sirolimus | Pfizer | phase 4 | 66 |
| gedatolisibrule | Pfizer | phase 3 | 9 |
| PI3K/mTOR Kinase Inhibitor WXFL10030390rule | shanghai-jiatan-pharmatech-co-ltd | phase 3 | 6 |
Studies
All 14 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07558733Breast Neoplasms · United States | 2 | Recruiting | Faeth Therapeutics | May 2029 | 32 |
| NCT06463028Endometrial Neoplasms · United States | 2 | Recruiting | Faeth Therapeutics | Sep 2028 | 40 |
| NCT05275673Carcinoma, Non-Small-Cell Lung · United States | 2 | Terminated | Faeth Therapeutics | Jan 24, 2023 | 7 |
| NCT03370302Advanced Nonhematological Neoplasms · Japan, Korea, Republic of, Taiwan | 1 | Terminated | Calithera Biosciences | Aug 28, 2019 | 28 |
| NCT02756364Breast Neoplasms · United States, Spain | 2 | Completed | Calithera Biosciences | Nov 25, 2019 | 141 |
| NCT02725268Endometrial Neoplasms · United States, Australia, Belgium and more | 2 | Completed | Takeda | Jul 2, 2019 | 241 |
| NCT02724020Clear-cell metastatic renal cell carcinoma · United States, Canada, Czechia and more | 2 | Completed | Takeda | Feb 3, 2020 | 96 |
| NCT02197572Advanced Solid Tumors · United States | 1 | Completed | Calithera Biosciences | Jun 10, 2016 | 44 |
| NCT01899053Advanced Nonhematologic Malignancies · United States, Spain, United Kingdom | 1 | Completed | Takeda | Jan 31, 2017 | 101 |
| NCT01351350Hematologic Neoplasms · United States | 1 | Completed | Takeda | Sep 15, 2017 | 68 |
| NCT01118689Multiple Myeloma · United States | 1 | Completed | Takeda | May 2013 | 39 |
| NCT01058707Advanced Solid Malignancies · United States, Spain | 1 | Completed | Takeda | Feb 7, 2019 | 198 |
| NCT00756041Diabetic Neuropathies | 2 | Terminated | Takeda | Sep 2006 | 221 |
| NCT00229437Diabetic Neuropathies · United States, Canada | 2 | Completed | Takeda | May 2006 | 343 |
How it is read
Names in the registry
- “Sapanisertib”, 5 entries
- “MLN0128”, 4 entries
- “TAK-128”, 4 entries
- “TAK-228”, 2 entries
- “sapanisertib”, 1 entry
Codes read as this program: TAK128.
Conditions, from the studies’ own filings
- Breast Neoplasms, 2 studies
- Endometrial Neoplasms, 2 studies
- Diabetic Neuropathies, 2 studies
- Carcinoma, Non-Small-Cell Lung, 1 study
- Clear-cell metastatic renal cell carcinoma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.